The striking sensitivity of breast related cancer antigens 1 and 2 (BRCA1/2) deficient tumour cells to poly (ADP-ribose) polymerase PARP inhibition have been demonstrated in 2005. The gene discussed is PARP1; the disease is neoplasm.